Phase II Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil Chemotherapy in Squamous Cell Carcinoma of the Oral Cavity With Molecular Endpoints.

Trial Profile

Phase II Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil Chemotherapy in Squamous Cell Carcinoma of the Oral Cavity With Molecular Endpoints.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 06 Dec 2010 Planned End Date changed from 1 Jan 2020 to 1 Sep 2009 as reported by ClinicalTrials.gov.
    • 01 Oct 2008 Planned number of patients changed from 20 to 60, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top